SIGA awarded Department of Defense contract to develop expanded indication for TPOXX®
SIGA Technologies announced it has been awarded a multi-year contract from the U.S. DoD to support work necessary to gain a potential label expansion for TPOXX® (tecovirimat) that would include Post-Exposure Prophylaxis (PEP) of smallpox. The contract is valued at up to $19.5 million. July 08, 2019
